JOSÉ LUIS
DÍEZ MARTÍN
Profesor titular de universidad
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (60)
2024
-
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients
Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12
2023
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4
-
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission
British Journal of Haematology, Vol. 201, Núm. 6, pp. 1169-1178
-
Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing
Cancers, Vol. 15, Núm. 3
-
Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide
Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567
-
Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
HemaSphere
-
Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
Cancers, Vol. 15, Núm. 12
2022
-
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 968-980
-
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy
Transfusion, Vol. 62, Núm. 10, pp. 2143-2147
-
Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
Bone Marrow Transplantation, Vol. 57, Núm. 5, pp. 817-823
-
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
Frontiers in immunology, Vol. 13, pp. 1002959
-
Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide
Transfusion, Vol. 62, Núm. 2, pp. 374-385
-
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
Bone Marrow Transplantation, Vol. 57, Núm. 11, pp. 1657-1663
-
Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9)
Bone Marrow Transplantation
-
Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment (BMC Cancer, (2022), 22, 1, (982), 10.1186/s12885-022-10070-z)
BMC Cancer
-
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
BMC Cancer, Vol. 22, Núm. 1
-
FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 16
-
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age
American Journal of Hematology, Vol. 97, Núm. 8, pp. 1065-1074